Novo Nordisk is reportedly searching for obesity experts to staff an R&D centre, Merck Serono gets a new CEO, and we look at the latest biopharmaceutical hires.
Xellia has agreed to invest $100m in equipment, retain staff and create 40 full time jobs at the plant it bought in Raleigh, North Carolina in return for business incentives.
Novo Nordisk has bought a biomanufacturing facility earmarked for closure by Olympus Biotech and begun rehiring staff in order to support its haemophilia product pipeline.
Novo Nordisk wants “a political debate” and changes to financial disclosure laws after Danish authorities fined it $90,000 for not immediately telling investors the US FDA had rejected Tresiba and Ryzodeg in 2013.
Debate rages over the significance of safety data from a trial of Oramed’s oral insulin pill, but the firm is still confident in its delivery technology.
Novo Nordisk's North American affiliate has a new President and more news from drug delivery firm Enteris - welcome to in-Pharmatechnologist.com' People on the Move.
Novo Nordisk says the $69 investment in its Danish plant will convert capacity ready for its new GLP-1 analogue and is a further commitment to Danish manufacturing.
Jerusalem, Israel-based drugmaker Oramed Pharmaceuticals has been granted patent approval for its oral insulin technology by the Japanese Patent office.
Novo Nordisk says “there is still room for improvement” in the development and delivery of insulin as it awaits FDA approval of its challenge to Lantus.
in-Pharmatechnologist brings you the lowdown of the latest new faces within the pharmaceutical industry, including news from Novo Nordisk, Generix, and Watson Pharma.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Penn Pharma, Omnicare, TranScrip Partners and Selvita.
The knowledge and means are in place to implement real-time release (RTR), a PAT pioneer said at AAPS, but questions remain about whether pharma has the will and desire.
Novo Nordisk is investing $73m in the expansion of its manufacturing facility in Clayton, North Carolina, to make room for increased production capacity for the biopharma giant’s insulin delivery services.
Danish biopharma giant, Novo Nordisk is expanding its R&D Centre in China by introducing a new Diabetes Research unit and doubling its quota of employees from 100 to 200 by 2015.
Packaging group Stralfors says its recent collaboration with Novo Nordisk proves that its service plan is ideal for projects with strict time-to-market requirements.
Schlafender Hase has launched a new version of its text verification tool (TVT) that supports all major languages, allowing pharma packagers in all regions to check labels prior to shipping.
Clinical trial software provider Phase Forward posted strong Q1 financial results, with CRO related revenues jumping by 52 per cent despite the difficulties facing companies in the sector.
Although it is widely acknowledged that medical bracelets can be the difference between life and death, Australia’s Nanotechnology Victoria (NanoVic) has become the first to take the idea further with its insulin-delivering jewellery project.
Irish oral dosage specialist Merrion Pharmaceuticals is to develop and commercialise Novo Nordisk’s range of insulin analogues as the Danish firm seeks to tighten its grip on the $9bn (€7bn) a year diabetes market.
Danish drugmaker Novo Nordisk has unveiled an ambitious plan to build an insulin plant in China, tapping into a major new market for diabetes treatments.
Novo Nordisk and Merck & Co have both indicated they have their
eye on expanding their drug discovery and manufacturing presence in
India and forging new research partnerships among companies in the
country.
Denmark's Novo Nordisk, could be on the verge of selling off its
engineering division, if reports in the local business daily Borsen
are to be believed.
Novo Nordisk, Rheosciences, ImClone, Omrix Biopharmaceuticals,
Biogen Idec and Human Genome Sciences, have all had people on the
move in the biotech world.
Despite numerous media reports of an impending patent infringement
suit, Sanofi-Aventis has yet to formally hear anything from
plaintiff Novo Nordisk, who claims the French firm's SoloStar
insulin pen violates patents covering...
Novo Nordisk has decided to stop developing small-molecule drugs
and instead concentrate on protein-based therapies, capitalising on
the strong growth in this sector of the pharmaceutical industry.
Novo Nordisk is planning to sue the head of the US Patent and
Trademark Office after its inhaled insulin product has had its
patent application knocked back for the second time.
By 2010 nearly half of all mid pharma firm revenues will be derived
from products that have been discovered outside of in-house
development pipelines, says a new report from independent market
analyst Datamonitor.
Indian IT company Tata Consultancy Services (TCS) has scored a
contract from Danish pharma company Novo Nordisk for the data
management of its clinical trials run in India.
Danish pharmaceutical company Novo Nordisk has filed a lawsuit
against France's Sanofi-Aventis, alleging that the latter has
infringed patent protection for an insulin injection system for
diabetes patients.
Singapore contract biologics manufacturer A-Bio has added another
top pharmaceutical company to its list of customers, just over 18
months after starting operations, reports Phil Taylor.
The Danish NovoSeven Facility has been given the '2005 Facility of
the Year Award' by the foremost representatives of the
pharmaceutical industry's international engineering society.
Danish pharmaceutical firm Novo Nordisk has announced plans for a
significant expansion of its production facilities in China,
expanding its capabilities to accommodate the increasing demand for
its FlexPen, NovoPen and Penfill products.
European companies have announced hefty spending on new
manufacturing facilities this month, suggesting that despite a
difficult operating environment the pharmaceutical sector is still
prepared to make significant capital investments